144 related articles for article (PubMed ID: 1637562)
1. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis.
Kerscher MJ; Korting HC
Skin Pharmacol; 1992; 5(2):77-80. PubMed ID: 1637562
[TBL] [Abstract][Full Text] [Related]
2. 0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations increase skin surface roughness: a possible dissociation of unwanted epidermal and dermal effects.
Kerscher MJ; Korting HC; Mehringer L; Mätzig R
Skin Pharmacol; 1996; 9(2):120-3. PubMed ID: 8722606
[TBL] [Abstract][Full Text] [Related]
3. 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream.
Korting HC; Vieluf D; Kerscher M
Eur J Clin Pharmacol; 1992; 42(2):159-61. PubMed ID: 1618247
[TBL] [Abstract][Full Text] [Related]
4. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study.
Queille-Roussel C; Paul C; Duteil L; Lefebvre MC; Rapatz G; Zagula M; Ortonne JP
Br J Dermatol; 2001 Mar; 144(3):507-13. PubMed ID: 11260007
[TBL] [Abstract][Full Text] [Related]
5. Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: a randomized controlled trial.
Fesq H; Lehmann J; Kontny A; Erdmann I; Theiling K; Rother M; Ring J; Cevc G; Abeck D
Br J Dermatol; 2003 Sep; 149(3):611-9. PubMed ID: 14510997
[TBL] [Abstract][Full Text] [Related]
6. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
Kerscher MJ; Korting HC
Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis.
Mensing H; Korsukewitz G; Yawalkar S
J Am Acad Dermatol; 1991 Dec; 25(6 Pt 2):1149-52. PubMed ID: 1757606
[TBL] [Abstract][Full Text] [Related]
8. Response of segmental vitiligo to 0.05% clobetasol propionate cream.
Khalid M; Mujtaba G
Int J Dermatol; 1998 Sep; 37(9):705-8. PubMed ID: 9762827
[No Abstract] [Full Text] [Related]
9. A comparison of the potencies of several diluted and undiluted corticosteroid preparations using the vasoconstrictor assay.
Kirsch J; Gibson JR; Darley CR; Burke CA
Dermatologica; 1983; 167(3):138-41. PubMed ID: 6195026
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.
Lebwohl M; Sherer D; Washenik K; Krueger GG; Menter A; Koo J; Feldman SR
Int J Dermatol; 2002 May; 41(5):269-74. PubMed ID: 12100701
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
Cossmann M; Welzel J
Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
[TBL] [Abstract][Full Text] [Related]
12. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis.
Maloney JM; Morman MR; Stewart DM; Tharp MD; Brown JJ; Rajagopalan R
Int J Dermatol; 1998 Feb; 37(2):142-4. PubMed ID: 9542676
[TBL] [Abstract][Full Text] [Related]
13. Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse.
van der Vleuten CJ; van Vlijmen-Willems IM; de Jong EM; van de Kerkhof PC
Arch Dermatol Res; 1999; 291(7-8):390-5. PubMed ID: 10482007
[TBL] [Abstract][Full Text] [Related]
14. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis.
Jacobson C; Cornell RC; Savin RC
Cutis; 1986 Mar; 37(3):213-4, 216, 218-20. PubMed ID: 3514155
[TBL] [Abstract][Full Text] [Related]
15. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.
Lévy J; Gassmüller J; Schröder G; Audring H; Sönnichsen N
Skin Pharmacol; 1994; 7(4):231-6. PubMed ID: 8024805
[TBL] [Abstract][Full Text] [Related]
17. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
[TBL] [Abstract][Full Text] [Related]
18. [Reducing the dosage by new technology].
Steinhorst M
Hautarzt; 2001 Jan; 52(1):p following 90 (91). PubMed ID: 11220248
[No Abstract] [Full Text] [Related]
19. Comparison of topical tacrolimus 0.1 % in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: a 4-week, randomized, double-blind clinical trial.
Petruzzi M; De Benedittis M; Serpico R
Clin Ther; 2007 Feb; 29(2):385; author reply 386. PubMed ID: 17472834
[No Abstract] [Full Text] [Related]
20. Evaluation of topical application of clobetasol 17-propionate from various cream bases.
Fang JY; Shen KL; Huang YB; Wu PC; Tsai YH
Drug Dev Ind Pharm; 1999 Jan; 25(1):7-14. PubMed ID: 10028413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
